Overview

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

Status:
ENROLLING_BY_INVITATION

Trial end date:
2027-06-01

Target enrollment:

Participant gender:

Summary

Children with relapsed or refractory Hodgkin lymphoma receive 3-6 cycles of nivolumab monotherapy. In case of achieving complete response (CR) auto-HSCT is performed. In the absence of CR, 3-6 additional cycles of nivolumab with bendamustine are administered. If complete or partial response is achieved, auto-HSCT is performed.

Phase:

PHASE2

Details

Lead Sponsor:

St. Petersburg State Pavlov Medical University

Treatments:

Bendamustine Hydrochloride
Nivolumab